Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.55 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | GLB1 | P16278 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 3/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18236645 | 0.84 | GLB1 (0.52) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL2325468 | 0.82 | GBA1 (0.42) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL18236649 | 0.82 | GLB1 (0.50) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL23767404 | 0.80 | GUSB (0.59) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL19275301 | 0.79 | GUSB (0.59) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL20858345 | 0.79 | GUSB (0.59) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL13182863 | 0.79 | EBP (0.59) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL20858275 | 0.79 | GUSB (0.59) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL15363044 | 0.78 | EBP (0.63) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL15362952 | 0.77 | EBP (0.62) | GUSBEBPSIGMAR1GLB1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41439-E1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1289996-B1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | GUSB 1356/4885EBP 3459/4885SIGMAR1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.